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Introduction {#cam41178-sec-0001}
============

The 5‐year survival rate of pancreatic ductal adenocarcinoma (PDAC) patients remains poor relative to other gastrointestinal malignancies [1](#cam41178-bib-0001){ref-type="ref"}, [2](#cam41178-bib-0002){ref-type="ref"}, even after complete curative resection. Recently, the 5‐year survival rates have improved due to various developments in pre‐ and postoperative chemo‐ and chemoradiotherapy. Neoadjuvant chemoradiotherapy (NACRT) is considered an acceptable treatment for locally advanced PDAC [3](#cam41178-bib-0003){ref-type="ref"}, [4](#cam41178-bib-0004){ref-type="ref"}, and postoperative adjuvant chemotherapy has been widely administered [5](#cam41178-bib-0005){ref-type="ref"}, [6](#cam41178-bib-0006){ref-type="ref"}. However, the 5‐year survival rate of PDAC patients remains low despite the development of these multimodal therapies.

Several retrospective studies [7](#cam41178-bib-0007){ref-type="ref"}, [8](#cam41178-bib-0008){ref-type="ref"}, [9](#cam41178-bib-0009){ref-type="ref"} have reported that a proportion of patients who underwent curative resection for PDAC have survived for \>5 years. Almost all the factors predictive of 5‐year survival in these studies [7](#cam41178-bib-0007){ref-type="ref"}, [8](#cam41178-bib-0008){ref-type="ref"}, [9](#cam41178-bib-0009){ref-type="ref"} are associated with pathological data (e.g., resection margin and lymph node metastasis status). However, clinical factors that predict long‐term survival in PDAC patients, especially pre‐ and postoperative chemo‐ or chemoradiotherapy and preoperative laboratory data, have yet to be fully elucidated.

In this study, we aimed to investigate pre‐ and postoperative clinicopathological characteristics of PDAC patients who survived for \>5 years after curative resection, focusing on pre‐ and postoperative chemo‐ or chemoradiotherapy and preoperative laboratory data.

Materials and Methods {#cam41178-sec-0002}
=====================

Patients {#cam41178-sec-0003}
--------

Patients who underwent intended curative pancreatectomy for PDAC at our institution between January 1995 and December 2011 were retrospectively reviewed. All patients were histologically confirmed as having PDAC. We excluded patients who underwent R2 resections. All study participants had provided informed written consent. The Human Experimentation Committee of our institution approved this study. Research was conducted in accordance with the Declaration of Helsinki.

Patients were stratified into two groups according to survival: the 5‐year survival group (patients who survived for \>5 years) and the \<5‐year survival group (patients who died or were lost to follow‐up within 5 years of curative pancreatectomy).

Preoperative assessment {#cam41178-sec-0004}
-----------------------

The demographic and clinical variables included age, gender, body mass index, operative procedure, NACRT, tumor size, and preoperative laboratory data. The biochemical profile included total bilirubin, albumin, and globulin levels; the albumin‐to‐globulin ratio; [10](#cam41178-bib-0010){ref-type="ref"} cholinesterase and total cholesterol levels; white blood cell \[WBC\] count; neutrophil, lymphocyte, and platelet counts; the neutrophil‐to‐lymphocyte ratio [11](#cam41178-bib-0011){ref-type="ref"}. Markers such as C‐reactive protein \[CRP\], fibrinogen, carcinoembryonic antigen \[CEA\], carbohydrate antigen 19‐9 \[CA 19‐9\], elastase‐1, duke pancreatic monoclonal antigen type‐2 \[DUPAN‐2\], and s‐pancreas antigen‐1 \[SPAN‐1\] levels; and the CRP‐to‐albumin ratio [12](#cam41178-bib-0012){ref-type="ref"} were included. The prognostic nutritional index (PNI) [13](#cam41178-bib-0013){ref-type="ref"} and modified Glasgow Prognostic Score (mGPS) [14](#cam41178-bib-0014){ref-type="ref"}, useful predictors of prognosis in PDAC patients, were also included.

Since 2003, at our institution, NACRT has been administered to patients who were diagnosed with T3‐4 disease according to the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumors (seventh edition). NACRT consisted of 40.0 Gy of radiation (2.0 Gy/day, days 1--5 each week, for 4 weeks), 5‐fluorouracil (5‐FU; 300.0 mg/day by continuous intravenous infusion, days 1--5 each week, for 4 weeks), mitomycin C (4.0 mg/\[body∙day\] by intravenous bolus, days 1, 8, 15, and 22), cisplatin (10.0 mg/\[body∙day\] by intravenous bolus, days 2, 9, 16, and 23), and heparin (6000 IU/\[body∙day\] by continuous intravenous infusion, days 1--7 each week for 4 weeks) [15](#cam41178-bib-0015){ref-type="ref"}.

Surgical resection and pathology {#cam41178-sec-0005}
--------------------------------

Surgical resection included pancreaticoduodenectomy, distal pancreatectomy, and total pancreatectomy. D2 lymph node dissections were performed in all patients.

Pathological staging of all specimens was determined according to the UICC TNM Classification of Malignant Tumors (seventh edition). R0 resections were defined as cases without gross or microscopic evidence of residue disease. R1 resections had microscopically positive margins and R2 resections still contained some gross tumor matter. Pathological features associated with prognosis included histologically assessed tumor size; distal bile duct, duodenal, serosal, retropancreatic tissue, portal venous or arterial system, and extrapancreatic nerve plexus invasion; other organ invasion; lymph node metastasis; and lymphatic, venous, or intrapancreatic neural infiltration [16](#cam41178-bib-0016){ref-type="ref"}.

Postoperative assessment {#cam41178-sec-0006}
------------------------

Since the year 1986, perioperative portal vein infusion (PVI) chemotherapy has been performed as a standard treatment to prevent liver recurrence and improve survival in pancreatic cancer patients undergoing potentially curative resection at our institution. PVI was adopted in only those patients who gave informed consent for this treatment. PVI chemotherapy consisted of 5‐FU and heparin (250.0 mg/day and 2000 IU/\[body∙day\], days 1--7 each week for 4 weeks), mitomycin C (4.0 mg/\[body∙day\], days 6, 13, 20, and 27), and cisplatin (10.0 mg/\[body∙day\], days 7, 14, 21, and 28) [17](#cam41178-bib-0017){ref-type="ref"}, [18](#cam41178-bib-0018){ref-type="ref"}. S‐1, gemcitabine, 5‐FU, or mitomycin C was administered as adjuvant chemotherapy at the physician\'s discretion. Postoperative complications were evaluated according to the Clavien‐Dindo classification. In this study, pancreatic fistulas, intra‐abdominal bleeding, delayed gastric emptying, and fluid collection were also investigated.

Follow‐up {#cam41178-sec-0007}
---------

Patients were followed‐up 1, 3, 6, and 12 months after surgery. Patients were also subject to semiannual reviews. Clinical examinations, laboratory investigations, and abdominal computed tomography scans (to detect tumor recurrence) were performed. Disease‐free survival (DFS) was calculated from the date of surgery to the date of recurrence or last follow‐up and overall survival (OS) was calculated from the date of surgery to the date of death or last follow‐up. Patients were followed up until death or December 2016.

Statistical analyses {#cam41178-sec-0008}
--------------------

The clinicopathological characteristics between the 5‐year survival and \<5‐year survival groups were evaluated and factors predictive of achieving 5‐year survival were investigated using logistic regression analysis. The optimal cut‐off points for predicting 5‐year survival were estimated from a receiver operating characteristic (ROC) curve analysis. Survival curves were plotted using the Kaplan--Meier method and compared by the log‐rank test. Variables that were significant in the univariate analysis were included in the multivariate analysis to identify prognostic factors of survival. All statistical analyses were conducted using Statistical Package for the Social Sciences for Macintosh, software version 23.0 (IBM Corp., Armonk, NY). A *P *\<* *0.05 was considered statistically significant.

Results {#cam41178-sec-0009}
=======

Patient characteristics and surgical procedures {#cam41178-sec-0010}
-----------------------------------------------

In total, 153 patients underwent curative resection for PDAC between January 1995 and December 2011. Two patients who underwent R2 resections were excluded. Therefore, 151 patients were enrolled in the final study. The patient characteristics are summarized in Table [1](#cam41178-tbl-0001){ref-type="table-wrap"}.

###### 

Patient characteristics

  Characteristic                                                          Patients (*N* = 151)
  ----------------------------------------------------------------------- ----------------------
  Gender, *N* (%)                                                         
  M                                                                       94 (62.3)
  F                                                                       57 (37.7)
  Age (years), median (range)                                             67 (46--83)
  NACRT, *N* (%)                                                          23 (15.2)
  Surgical procedure, *N* (%)                                             
  Pancreaticoduodenectomy                                                 96 (63.6)
  Distal pancreatectomy                                                   48 (31.8)
  Total pancreatectomy                                                    7 (4.6)
  UICC Stage, *N* (%)[a](#cam41178-note-0004){ref-type="fn"}              
  IA                                                                      6 (4.0)
  IB                                                                      7 (4.6)
  IIA                                                                     36 (23.8)
  IIB                                                                     89 (58.9)
  III                                                                     1 (0.7)
  IV                                                                      12 (8.0)
  Perioperative PVI chemotherapy, *N* (%)                                 79 (52.3)
  Adjuvant chemotherapy, *N* (%)[b](#cam41178-note-0005){ref-type="fn"}   43 (28.5)
  LNM, *N* (%)                                                            
  Positive                                                                101 (66.9)
  Negative                                                                50 (33.1)
  Resection status, *N* (%)                                               
  R0                                                                      110 (72.8)
  R1                                                                      41 (27.2)

5‐FU, 5‐fluorouracil; F, female; LNM, lymph node metastasis; M, male; NACRT, neoadjuvant chemoradiotherapy; PVI, portal vein infusion; UICC, Union for International Cancer Control.

Pathological stage, UICC TNM Classification of Malignant Tumors (seventh edition).

S‐1, gemcitabine, mitomycin C, or 5‐FU.

John Wiley & Sons, Ltd

Of the 151 patients, 38 (25.2%) were included in the 5‐year survival group and 113 (74.8%) were included in the \<5‐year survival group. The actual 5‐year survival rate was 25.2%. The median follow‐up duration of the 5‐year survival group was 84 (range, 60--197) months. Sixteen patients (42.1%) survived without recurrence and seven patients (18.4%) survived with recurrence (local \[*N* = 3\], lungs \[*N* = 2\], liver \[*N* = 1\], and bone \[*N* = 1\]). Eleven patients (28.9%) died of PDAC and four patients (10.5%) died of other causes. The patterns of initial recurrence were local (*N* = 9; 23.7%), followed by the lungs (*N* = 6; 15.8%), liver (*N* = 4; 10.5%), lymph nodes (*N* = 4; 10.5%), and bone (*N* = 1; 2.6%).

Pre‐ and postoperative outcomes in the 5‐year survival and \<5‐year survival groups {#cam41178-sec-0011}
-----------------------------------------------------------------------------------

The preoperative data are summarized in Table [2](#cam41178-tbl-0002){ref-type="table-wrap"}. Several factors were identified in the univariate analysis as being significantly different between the 5‐year survival and \<5‐year survival groups, including NACRT, serum albumin levels, and the WBC and lymphocyte counts.

###### 

Univariate analysis of preoperative predictive factors

  Factor                                            5‐year survival (*N* = 38)   \<5‐year survival (*N* = 133)   *P*‐value
  ------------------------------------------------- ---------------------------- ------------------------------- -----------------------------------------------
  Age (years), median (range)                       65 (55--81)                  67 (46--83)                     0.211
  Sex (M/F)                                         24/14                        70/43                           0.894
  BMI (kg/m^2^), median (range)                     23.8 (16.4--40.0)            23.9 (15.8--33.4)               0.650
  Surgical procedure, *N* (%)                                                                                    0.226
  Pancreaticoduodenectomy                           20 (52.6)                    76 (67.3)                       0.121
  Distal pancreatectomy                             15 (39.5)                    33 (29.2)                       0.314
  Total pancreatectomy                              3 (7.9)                      4 (3.5)                         0.369
  NACRT, *N* (%)                                    12 (31.5)                    11 (9.7)                        0.003[\*](#cam41178-note-0009){ref-type="fn"}
  Tumor size (cm), *N* (%)                                                                                       
  \<4.0                                             35.0 (92.1)                  101.0 (89.4)                    0.628
  ≥4.0                                              3.0 (7.9)                    12.0 (10.6)                     0.628
  Total bilirubin level (mg/dL), median (range)     0.8 (0.3--4.2)               0.9 (0.4--6.5)                  0.252
  Albumin level (g/L), median (range)               4.0 (2.6--4.7)               3.8 (2.7--4.8)                  0.011[\*](#cam41178-note-0009){ref-type="fn"}
  Globulin level (g/L), median (range)              2.9 (0.3--4.0)               2.9 (1.9--4.2)                  0.981
  Albumin‐to‐globulin ratio, median (range)         0.3 (0.1--1.7)               0.3 (0.1--2.5)                  0.129
  Cholinesterase level (U/L), median (range)        248.0 (76.0--394.0)          241.0 (72.0--427.0)             0.664
  Total cholesterol level (mg/dL), median (range)   164.0 (94.0--257.0)          176.0 (94.0--303.0)             0.658
  WBC count (×10^3^/*μ*L), median (range)           4550 (1400--8400)            5300 (2000--12,400)             0.014[\*](#cam41178-note-0009){ref-type="fn"}
  Neutrophil count (×10^3^/*μ*L), median (range)    2881 (1106--7039)            3088 (1016--9696)               0.057
  Lymphocyte count (×10^3^/*μ*L), median (range)    1093 (164--2144)             1312 (453--3248)                0.019[\*](#cam41178-note-0009){ref-type="fn"}
  Neutrophil‐to‐lymphocyte ratio, median (range)    2.3 (1.0--7.4)               2.3 (0.5--11.0)                 0.584
  Platelet count (×10^3^/*μ*L), median (range)      197 (93--410)                216 (91--411)                   0.085
  CRP level (mg/L), median (range)                  0.2 (\<0.1--9.6)             0.2 (\<0.1--5.2)                0.545
  Fibrinogen level (mg/dL), median (range)          330.0 (130.0--714.0)         355.0 (182.0--669.0)            0.190
  CEA level (ng/mL), median (range)                 2.6 (0.8--52.6)              3.0 (0.9--60.9)                 0.425
  CA 19‐9 level (U/mL), median (range)              45.0 (1.0--7240.0)           88.0 (1.0--8820.0)              0.814
  Elastase‐1 level (ng/dL), median (range)          101.0 (40.0--1431.0)         215.0 (31.0--5230.0)            0.112
  DUPAN‐2 level (U/mL), median (range)              42.0 (25.0--3930.0)          175.0 (25.0--18,400.0)          0.186
  SPAN‐1 level (U/mL), median (range)               25.0 (6.0--228.0)            71.0 (6.0--3100.0)              0.091
  PNI, median (range)                               45.4 (34.8--54.6)            45.4 (32.2--62.3)               0.214
  CRP‐to‐albumin ratio, median (range)              0.040 (0.010--2.230)         0.040 (0.002--1.410)            0.724
  mGPS (0/1/2), *N*                                 31/7/0                       78/30/5                         0.080

BMI, body mass index; CA 19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CRP, C‐reactive protein; DUPAN‐2, Duke pancreatic monoclonal antigen type‐2; F, female; M, male; mGPS, modified Glasgow Prognostic Score; NACRT, neoadjuvant chemoradiotherapy; PNI, prognostic nutritional index; SPAN‐1, s‐pancreas antigen‐1; WBC, white blood cell.

*P *\<* *0.05.

John Wiley & Sons, Ltd

From the multivariate analysis, NACRT (odds ratio \[OR\]: 3.02, 95.0% confidence interval \[CI\]: 1.00--9.08; *P *=* *0.049) and serum albumin levels (OR: 5.06, 95.0% CI: 1.49--17.19; *P *=* *0.009) were confirmed as being independent predictive factors for achieving 5‐year survival (Table [3](#cam41178-tbl-0003){ref-type="table-wrap"}).

###### 

Multivariate analysis of preoperative predictive factors for achieving 5‐year survival

  Factor                           *P*‐value                                       OR     95.0% CI
  -------------------------------- ----------------------------------------------- ------ -------------
  NACRT                            0.049[\*](#cam41178-note-0009){ref-type="fn"}   3.02   1.00--9.08
  Albumin level (g/L)              0.009[\*](#cam41178-note-0009){ref-type="fn"}   5.06   1.49--17.19
  WBC count (×10^3^/*μ*L)          0.205                                           1.00   1.00--1.00
  Lymphocyte count (×10^3^/*μ*L)   0.432                                           1.00   0.99--1.00

CI, confidence interval; NACRT, neoadjuvant chemoradiotherapy; OR, odds ratio; WBC, white blood cell.

*P *\<* *0.05.

John Wiley & Sons, Ltd

The postoperative outcomes in these groups are displayed in Table [4](#cam41178-tbl-0004){ref-type="table-wrap"}. Lymphatic, venous, and neural infiltration; lymph node metastasis; pathological Stage IA and IIA‐B; perioperative PVI chemotherapy; and local, liver, and peritoneal recurrences were identified as predictive factors for achieving 5‐year survival in the univariate analysis. These factors were further analyzed in the multivariate analysis (Table [5](#cam41178-tbl-0005){ref-type="table-wrap"}). Venous infiltration (0--1) (OR: 2.99, 95.0% CI: 1.09--8.25; *P *=* *0.034), perioperative PVI chemotherapy (OR: 3.06, 95.0% CI: 1.09--8.25; *P *=* *0.028), and liver recurrence (OR: 0.17, 95.0% CI: 0.04--0.69; *P *=* *0.013) were confirmed as independent and significant predictive factors for achieving 5‐year survival.

###### 

Univariate analysis of postoperative predictive factors

  Factor                                                                  5‐Year survival (*N* = 38)   \<5‐Year survival (*N* = 113)   *P*‐value
  ----------------------------------------------------------------------- ---------------------------- ------------------------------- ------------------------------------------------
  Operative time (minutes), median (range)                                599 (259--1032)              587 (187--1173)                 0.934
  Blood loss (g), median (range)                                          583.0 (50.0--2800.0)         788.0 (30.0--5662.0)            0.278
  Postoperative complication, *N* (%)                                                                                                  
  Pancreatic fistula                                                      7 (18.4)                     36 (31.9)                       0.117
  Intra‐abdominal bleeding                                                1 (2.6)                      7 (6.2)                         0.411
  Delayed gastric emptying                                                1 (2.6)                      7 (6.2)                         0.411
  Fluid collection                                                        5 (13.2)                     12 (10.6)                       0.669
  Lymphatic infiltration, *N* (%)                                                                                                      
  0--1                                                                    27 (71.1)                    54 (47.8)                       
  2--3                                                                    11 (28.9)                    59 (52.2)                       0.015[a](#cam41178-note-0011){ref-type="fn"}
  Venous infiltration, *N* (%)                                                                                                         
  0--1                                                                    25 (65.8)                    43 (38.1)                       
  2--3                                                                    13 (34.2)                    70 (61.9)                       0.004[a](#cam41178-note-0011){ref-type="fn"}
  Neural infiltration, *N* (%)                                                                                                         
  0--1                                                                    21 (55.3)                    33 (29.2)                       
  2--3                                                                    17 (44.7)                    80 (70.8)                       0.005[a](#cam41178-note-0011){ref-type="fn"}
  LNM, *N* (%)                                                                                                                         
  Positive                                                                16 (42.1)                    87 (77.0)                       
  Negative                                                                22 (57.9)                    26 (23.0)                       \<0.001[a](#cam41178-note-0011){ref-type="fn"}
  Resection status, *N* (%)                                                                                                            
  R0                                                                      32 (84.2)                    78 (69.0)                       0.074
  R1                                                                      6 (15.8)                     35 (31.0)                       0.108
  UICC stage, *N* (%)[b](#cam41178-note-0012){ref-type="fn"}                                                                           
  IA                                                                      5 (13.2)                     1 (0.9)                         0.011[a](#cam41178-note-0011){ref-type="fn"}
  IB                                                                      3 (7.9)                      4 (3.5)                         0.282
  IIA                                                                     14 (36.8)                    22 (19.5)                       0.032[a](#cam41178-note-0011){ref-type="fn"}
  IIB                                                                     14 (36.8)                    75 (66.4)                       0.002[a](#cam41178-note-0011){ref-type="fn"}
  III                                                                     0 (0.0)                      3 (2.7)                         1.000
  IV                                                                      2 (5.3)                      10 (8.8)                        0.484
  Perioperative PVI chemotherapy, *N* (%)                                 27 (71.1)                    52 (46.0)                       0.009[a](#cam41178-note-0011){ref-type="fn"}
  Adjuvant chemotherapy, *N* (%)[c](#cam41178-note-0013){ref-type="fn"}   13 (34.2)                    30 (26.5)                       0.367
  Recurrence, *N* (%)                                                                                                                  
  Local                                                                   9 (23.7)                     59 (52.2)                       0.003[a](#cam41178-note-0011){ref-type="fn"}
  Liver                                                                   4 (10.5)                     45 (39.8)                       0.002[a](#cam41178-note-0011){ref-type="fn"}
  Lung                                                                    6 (15.8)                     12 (10.6)                       0.398
  Peritoneal                                                              4 (10.5)                     44 (38.9)                       0.003[a](#cam41178-note-0011){ref-type="fn"}

5‐FU, 5‐fluorouracil; LNM, lymph node metastasis; PVI, portal vein infusion; UICC, Union for International Cancer Control.

*P *\<* *0.05.

Pathological stage, UICC Classification of Malignant Tumors (seventh edition).

S‐1, gemcitabine, mitomycin C, or 5‐FU.

John Wiley & Sons, Ltd

###### 

Multivariate analysis of postoperative predictive factors for achieving 5‐year survival

  Factor                                              *P*‐value                                      OR      95.0% CI
  --------------------------------------------------- ---------------------------------------------- ------- --------------
  Infiltration (0--1)                                                                                        
  Lymphatic                                           0.458                                          0.64    0.20--20.70
  Venous                                              0.034[a](#cam41178-note-0015){ref-type="fn"}   2.99    1.09--8.25
  Neural                                              0.160                                          2.10    0.75--5.95
  LNM (+)                                             0.947                                          0.92    0.07--12.52
  UICC stage[b](#cam41178-note-0016){ref-type="fn"}                                                          
  IA                                                  0.116                                          12.33   0.54--283.60
  IIA                                                 0.475                                          2.07    0.28--15.35
  IIB                                                 0.474                                          0.46    0.28--15.35
  Perioperative PVI chemotherapy                      0.028[a](#cam41178-note-0015){ref-type="fn"}   3.06    1.09--8.25
  Recurrence                                                                                                 
  Local                                               0.257                                          0.51    0.16--1.63
  Liver                                               0.013[a](#cam41178-note-0015){ref-type="fn"}   0.17    0.04--0.69
  Peritoneal                                          0.076                                          0.28    0.07--1.15

CI, confidence interval; LNM, lymph node metastasis; OR, odds ratio; PVI, portal vein infusion; UICC, Union for International Cancer Control.

*P *\<* *0.05.

Pathological stage, UICC Classification of Malignant Tumors (seventh edition).

John Wiley & Sons, Ltd

Preoperative albumin levels and survival {#cam41178-sec-0012}
----------------------------------------

ROC curve analysis demonstrated that a preoperative serum albumin level of 3.9 g/dL (area under the curve, 0.670; *P *=* *0.002) was the optimal cut‐off for 5‐year survival. In the survival analysis according to the Kaplan--Meier method, patients with preoperative serum albumin levels of ≥3.9 g/dL had a significantly longer DFS compared to patients with preoperative serum albumin levels of \<3.9 g/dL (Fig. [1](#cam41178-fig-0001){ref-type="fig"}A; *P *=* *0.029). The OS of these patients was also longer, although this was not significant (Fig. [1](#cam41178-fig-0001){ref-type="fig"}B).

![Kaplan--Meier curves of (A) postoperative disease‐free survival (DFS) and (B) overall survival (OS) according to preoperative serum albumin levels.](CAM4-6-2278-g001){#cam41178-fig-0001}

Other predictive factors and survival {#cam41178-sec-0013}
-------------------------------------

Patients receiving NACRT did not have a significantly longer DFS (Fig. [2](#cam41178-fig-0002){ref-type="fig"}A). However, they did have a significantly longer OS (Fig. [2](#cam41178-fig-0002){ref-type="fig"}B; *P *=* *0.045). Adjuvant PVI chemotherapy was not a significant predictor of DFS (Fig. [2](#cam41178-fig-0002){ref-type="fig"}C), but was predictive of OS (Fig. [2](#cam41178-fig-0002){ref-type="fig"}D; *P *=* *0.05).

![Kaplan--Meier curves of (A, C) postoperative disease‐free survival (DFS) and (B, D) overall survival (OS) according to neoadjuvant chemoradiotherapy (NACRT) and perioperative adjuvant portal vein infusion (PVI).](CAM4-6-2278-g002){#cam41178-fig-0002}

Discussion {#cam41178-sec-0014}
==========

This study investigated the pre‐ and postoperative predictive factors related to survival in patients with 5‐year survival compared to those with \<5‐year survival. Our findings demonstrated that NACRT and preoperative serum albumin levels were independent preoperative predictive factors for achieving 5‐year survival. Additionally, venous infiltration, perioperative PVI chemotherapy, and liver recurrence were confirmed as independent postoperative predictive factors for achieving 5‐year survival.

By analyzing patients who survived for \>5 years, factors for achieving 5‐year survival could be identified more accurately. Previous retrospective studies [7](#cam41178-bib-0007){ref-type="ref"}, [8](#cam41178-bib-0008){ref-type="ref"}, [9](#cam41178-bib-0009){ref-type="ref"} have identified preoperative serum CA 19‐9 levels, multiple operations, lymph node metastasis, and R0 resections as prognostic factors in PDAC patients with an actual 5‐year survival after curative resection. These studies [7](#cam41178-bib-0007){ref-type="ref"}, [8](#cam41178-bib-0008){ref-type="ref"}, [9](#cam41178-bib-0009){ref-type="ref"} also reported 5‐year survival rates of 10.2--27.0%, although the periods of study varied. In this study, we reveal novel predictive factors: preoperative serum albumin levels, NACRT, perioperative PVI chemotherapy, venous infiltration, and liver recurrence.

NACRT has been used to reduce tumor volume and improve margin‐negative resection rates in patients with locally advanced PDAC [4](#cam41178-bib-0004){ref-type="ref"}, [19](#cam41178-bib-0019){ref-type="ref"}. A clinical trial [20](#cam41178-bib-0020){ref-type="ref"} has made progress. However, standardized protocols have yet to be established. At our institution, we began administering NACRT in 2003. We have previously reported [19](#cam41178-bib-0019){ref-type="ref"} on two cases of PDAC with pathological complete responses to NACRT and have included these cases in our 5‐year survival group. Katz et al. [9](#cam41178-bib-0009){ref-type="ref"} emphasized the importance of staging and patient selection, a standardized operative approach, and the routine use of multimodal therapy for achieving 5‐year survival rates.

Previous studies [21](#cam41178-bib-0021){ref-type="ref"}, [22](#cam41178-bib-0022){ref-type="ref"} have suggested that in patients with non--small‐cell lung cancer or epithelial ovarian cancer, preoperative serum albumin levels are associated with a predictive survival rate. Low serum albumin levels are associated with a risk of postoperative complications and poor survival outcomes because of malnutrition [23](#cam41178-bib-0023){ref-type="ref"}. The prognostic factors related to serum albumin levels (e.g., CRP‐to‐albumin ratio, PNI, and mGPS) [12](#cam41178-bib-0012){ref-type="ref"}, [13](#cam41178-bib-0013){ref-type="ref"}, [14](#cam41178-bib-0014){ref-type="ref"} have previously been identified in PDAC patients. However, few studies have reported that preoperative serum albumin levels alone can predict survival. Using prospective data from two randomized controlled trials [24](#cam41178-bib-0024){ref-type="ref"}, [25](#cam41178-bib-0025){ref-type="ref"}, Stocken et al. [26](#cam41178-bib-0026){ref-type="ref"} have identified serum albumin as one of the prognostic factors for survival in PDAC. We believe that preoperative serum albumin levels may represent a useful biomarker for predicting the prognosis of PDAC patients after resection.

We hypothesize that preoperative albumin levels may be influenced by several factors, including systemic inflammation, disease state, nutritional status, liver cirrhosis, and the quantity of skeletal muscle [27](#cam41178-bib-0027){ref-type="ref"}, [28](#cam41178-bib-0028){ref-type="ref"}, [29](#cam41178-bib-0029){ref-type="ref"}, [30](#cam41178-bib-0030){ref-type="ref"}, [31](#cam41178-bib-0031){ref-type="ref"}. Several studies [32](#cam41178-bib-0032){ref-type="ref"}, [33](#cam41178-bib-0033){ref-type="ref"}, [34](#cam41178-bib-0034){ref-type="ref"} have demonstrated that preoperative inflammation and postoperative complications can lead to poor survival outcomes in patients with various types of tumors. In our study, preoperative CRP levels, WBC counts, and fibrinogen levels, measured acute or chronic inflammatory markers, did not correlate with preoperative albumin levels (data not shown). Therefore, we speculate that preoperative serum albumin levels may reflect nutritional depletion and loss of skeletal muscle.

It remains unclear whether improving preoperative serum albumin levels can lead to a favorable prognosis. The criteria of the European Society for Clinical Nutrition and Metabolism [35](#cam41178-bib-0035){ref-type="ref"} demonstrate that low serum albumin levels is an established marker of malnutrition, and improving perioperative nutrition, especially immunonutrition, can result in reduced postoperative complications and hospital stays. In pancreatectomy, preoperative providing oral immunonutrition helps in reducing risk of postoperative complications such as infections, and also the length of hospital stays [36](#cam41178-bib-0036){ref-type="ref"}. From a molecular viewpoint, the overexpression of caspases and the reduced levels of antiapoptotic proteins in PDAC patients may lead to lymphocyte apoptosis and dysfunction and immune system suppression, especially after pancreatectomy [37](#cam41178-bib-0037){ref-type="ref"}. Therefore, improving perioperative immunonutrition may reduce the risk of immune disorders in patients with PDAC.

We consider it important to control for disease state and cancer recurrence. Among the 5‐year survivors, recurrence (especially liver recurrence) was a poor prognostic factor. To prevent liver recurrence and improve survival in PDAC patients who undergo potentially curative resections, we have administered perioperative PVI chemotherapy with 5‐FU at our institution since 1986 [17](#cam41178-bib-0017){ref-type="ref"}. We have already reported that perioperative PVI chemotherapy is beneficial in preventing liver recurrence [18](#cam41178-bib-0018){ref-type="ref"}, and in this study, perioperative PVI chemotherapy was identified as an independent postoperative predictive factor for achieving 5‐year survival.

In our univariate analysis, the pattern of initial recurrence (except lung recurrence) was a significant risk factor for achieving 5‐year survival. Several studies [38](#cam41178-bib-0038){ref-type="ref"}, [39](#cam41178-bib-0039){ref-type="ref"}, [40](#cam41178-bib-0040){ref-type="ref"} have revealed that patients with isolated lung recurrence as the initial recurrence followed a better course than patients with other recurrences [38](#cam41178-bib-0038){ref-type="ref"} for a variety of reasons. First, lung recurrence was more likely to occur late with a longer time to development than other sites of recurrence [39](#cam41178-bib-0039){ref-type="ref"}. Second, lung recurrence may be associated with unique and different phenotypes to those with other patterns of lung metastases in PDAC patients [38](#cam41178-bib-0038){ref-type="ref"}. Finally, the outcomes of patients who underwent reoperation for isolated lung recurrence were superior [40](#cam41178-bib-0040){ref-type="ref"}. In this study, patients with lung recurrence as the initial recurrence survived longer than patients with other patterns of recurrence (median OS: 45 vs. 18 months; *P *=* *0.008).

There are several limitations of this study. First, this was a retrospective study conducted at a single institution. Second, it was unclear whether improving preoperative serum albumin levels resulted in long‐term survival benefits after resection. Although the relationship between improving serum albumin levels and variations in oncological behavior is not well understood, several studies [26](#cam41178-bib-0026){ref-type="ref"}, [28](#cam41178-bib-0028){ref-type="ref"}, [29](#cam41178-bib-0029){ref-type="ref"}, [41](#cam41178-bib-0041){ref-type="ref"} have demonstrated an association between hypoalbuminemia and poor postoperative short‐/long‐term survival in patients with various types of malignancies. We believe that preoperative serum albumin levels represent a potential biomarker for predicting prognosis in PDAC patients after curative resection. However, further studies will need to be conducted in order to evaluate the relationship between serum albumin levels and improved survival after pancreatectomy.

In conclusion, preoperative serum albumin levels may represent a useful biomarker for predicting prognosis in PDAC patients after curative resection. This factor was more straightforward in clinical situations than other prognostic factors that are related to serum albumin levels (e.g., the CRP to albumin ratio, PNI, and mGPS). NACRT and perioperative PVI chemotherapy were also identified as significant predictive factors. Patients with liver recurrence were more likely to have a poor prognosis. Therefore, perioperative chemotherapy (e.g., PVI) is well suited to improve survival after pancreatectomy.
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